Calidi Biotherapeutics Files 8-K
Ticker: CLDWW · Form: 8-K · Filed: Sep 12, 2024 · CIK: 1855485
| Field | Detail |
|---|---|
| Company | Calidi Biotherapeutics, Inc. (CLDWW) |
| Form Type | 8-K |
| Filed Date | Sep 12, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing, financials, regulatory
Related Tickers: CLDI
TL;DR
Calidi Biotherapeutics filed an 8-K on 9/11/24 covering Reg FD and financials.
AI Summary
Calidi Biotherapeutics, Inc. filed an 8-K on September 11, 2024, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as First Light Acquisition Group, Inc. until April 6, 2021, is incorporated in Delaware and headquartered in San Diego, CA.
Why It Matters
This filing provides updates on regulatory disclosures and financial statements, which are crucial for investors to assess the company's current standing and future prospects.
Risk Assessment
Risk Level: low — This is a routine filing of an 8-K, not indicating any immediate material adverse events.
Key Numbers
- 001-40789 — SEC File Number (Identifies the company's filing with the SEC)
- 86-2967193 — IRS Number (Company's Employer Identification Number)
Key Players & Entities
- Calidi Biotherapeutics, Inc. (company) — Registrant
- First Light Acquisition Group, Inc. (company) — Former Company Name
- September 11, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- San Diego, CA (location) — Business Address City and State
FAQ
What specific Regulation FD Disclosure is being made in this 8-K?
The filing indicates a Regulation FD Disclosure, but the specific details of the disclosure are not provided in the provided text snippet.
What are the key exhibits included with this 8-K filing?
The filing states 'Financial Statements and Exhibits' are included, but the specific list of exhibits is not detailed in the provided text.
When did Calidi Biotherapeutics, Inc. change its name from First Light Acquisition Group, Inc.?
The company's name was changed from First Light Acquisition Group, Inc. on April 6, 2021.
What is Calidi Biotherapeutics, Inc.'s primary business classification?
The company is classified under 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)' with SIC code 2836.
Where is Calidi Biotherapeutics, Inc. headquartered?
The company's business address is located at 4475 Executive Drive, Suite 200, San Diego, CA 92121.
Filing Stats: 605 words · 2 min read · ~2 pages · Grade level 11.6 · Accepted 2024-09-12 06:12:24
Key Financial Figures
- $0.0001 — ch Registered Common stock, par value $0.0001 per share CLDI NYSE American LLC
Filing Documents
- form8-k.htm (8-K) — 42KB
- ex99-1.htm (EX-99.1) — 35KB
- ex99-1_001.jpg (GRAPHIC) — 105KB
- ex99-1_002.jpg (GRAPHIC) — 695KB
- ex99-1_003.jpg (GRAPHIC) — 89KB
- ex99-1_004.jpg (GRAPHIC) — 149KB
- ex99-1_005.jpg (GRAPHIC) — 124KB
- ex99-1_006.jpg (GRAPHIC) — 87KB
- ex99-1_007.jpg (GRAPHIC) — 124KB
- ex99-1_008.jpg (GRAPHIC) — 94KB
- ex99-1_009.jpg (GRAPHIC) — 91KB
- ex99-1_010.jpg (GRAPHIC) — 98KB
- ex99-1_011.jpg (GRAPHIC) — 128KB
- ex99-1_012.jpg (GRAPHIC) — 103KB
- ex99-1_013.jpg (GRAPHIC) — 113KB
- ex99-1_014.jpg (GRAPHIC) — 125KB
- ex99-1_015.jpg (GRAPHIC) — 139KB
- ex99-1_016.jpg (GRAPHIC) — 121KB
- ex99-1_017.jpg (GRAPHIC) — 111KB
- ex99-1_018.jpg (GRAPHIC) — 106KB
- ex99-1_019.jpg (GRAPHIC) — 111KB
- ex99-1_020.jpg (GRAPHIC) — 109KB
- ex99-1_021.jpg (GRAPHIC) — 120KB
- ex99-1_022.jpg (GRAPHIC) — 101KB
- ex99-1_023.jpg (GRAPHIC) — 138KB
- ex99-1_024.jpg (GRAPHIC) — 141KB
- ex99-1_025.jpg (GRAPHIC) — 124KB
- ex99-1_026.jpg (GRAPHIC) — 100KB
- ex99-1_027.jpg (GRAPHIC) — 78KB
- 0001493152-24-035939.txt ( ) — 5294KB
- cldi-20240911.xsd (EX-101.SCH) — 4KB
- cldi-20240911_def.xml (EX-101.DEF) — 29KB
- cldi-20240911_lab.xml (EX-101.LAB) — 36KB
- cldi-20240911_pre.xml (EX-101.PRE) — 26KB
- form8-k_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CALIDI BIOTHERAPEUTICS, INC. Dated: September 12, 2024 By: /s/ Andrew Jackson Name: Andrew Jackson Title: Chief Financial Officer